Homoeopathy as adjuvant in management of Covid-19 infectio
Phase 2
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/05/024969
- Lead Sponsor
- aiminath Homoeopathic Medical College Hospital and Research Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
oSymptomatic RT-PCR confirmed cases of
Covid-19 infection.
oBoth sexes
oAge between 18 years to 80 years and
oWilling to give signed written informed
consent
Exclusion Criteria
1.Patients requiring ventilatory support
2.Patients with compromised immunity
3.Severe heart, lung, kidney, brain, blood
diseases or other important systemic
diseases
4.Subjects unable to complete the study, or
not suitable for the study by
researchers.
5.Women during pregnancy
6.Lactating mothers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie homoeopathy's adjuvant effects in SARS-CoV-2 infection?
How does homoeopathy compare to standard-of-care treatments in reducing viral load and symptoms in CTRI/2020/05/024969?
Are there specific biomarkers that predict response to homoeopathy in coronavirus disease subtypes?
What adverse events are associated with homoeopathy as an adjuvant in CTRI/2020/05/024969 and how are they managed?
What combination therapies show promise alongside homoeopathy for managing SARS-CoV-2 infections?